recombinant human thrombin recothrom (ZymoGenetics inc)
90
Structured Review
ZymoGenetics inc
recombinant human thrombin recothrom
Recombinant Human Thrombin Recothrom, supplied by ZymoGenetics inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+thrombin+recothrom/recombinant+human+thrombin+recothrom/pm37897228-152-4-10
Average 90 stars, based on 1 article reviews
Recombinant Human Thrombin Recothrom, supplied by ZymoGenetics inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+thrombin+recothrom/recombinant+human+thrombin+recothrom/pm37897228-152-4-10
Average 90 stars, based on 1 article reviews
recombinant human thrombin recothrom - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Purification:Article Title: Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke Article Snippet: .. The purified 3K3A-PC zymogen was then activated with recombinant Recombinant:Article Title: Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke Article Snippet: .. The purified 3K3A-PC zymogen was then activated with recombinant Article Title: Bleeding and management of coagulopathy. Article Snippet: The first available thrombin was derived from bovine plasma (Thrombin-JMI, King Pharmaceuticals, Bristol, Tenn). .. Bovine thrombin currently should be avoided because of its potential for antibovine thrombin antibody formation and immune-mediated coagulopathy.37 Currently, there are 2 human thrombins available for clinical use, including plasma-derived thrombin (Evithrom; Omrix, Somerville, NJ, and Johnson & Johnson, New Brunswick, NJ) and Article Title: Managing clotting Article Snippet: Purpose of review Bleeding in a perioperative setting occurs due to multiple causes, but newer anticoagulant and antiplatelet therapies are increasingly used preoperatively.. As a result, patients often can present for surgery with underlying hemostatic disorders due to these acquired disorders or following major surgery or trauma.. Because bleeding occurs due to multiple causes, the addition of pharmacologic agents creates an acquired defect that complicates the surgical injury and may result in increased blood loss. Article Title: Update on blood conservation for cardiac surgery. Article Snippet: t n a t PATIENTS UNDERGOING CARDIAC SURGERY are at risk of excessive bleeding, leading to increased usage of allogeneic blood and hemostatic blood products.. Although this patient population represents a relatively small proportion of surgical patients, cardiac surgery consumes about 20% of the available blood supply in the United States,1 with similar numers reported worldwide.2,3 The potential for beneficial effects of transfusing blood to maintain tissue oxygen perfusion and prevent organ ischemia may be greatest in patients with cardiovascular disease.4 Indeed, life-threatening hemorrhage, an absolute indication for blood transfusion, may be relatively frequent in these patients, with repeat surgery for bleeding occurring in up to 5% of patients.5,6 In addition, the risks of reexisting anemia and acute perioperative hemodilution have ecome more apparent.7,8 However, there is a lack of clinical utcome data to support the liberal use of blood transfusion in ardiac surgery.9 In contrast, there is a growing body of evidence demonstrating that blood product transfusion is associated with an increased risk of morbidity and mortality.10-12 The considerable ariability in the transfusion of blood and blood products (8% o 98%) among institutions13-15 and countries13,14,16 may reflect he lack of a clear understanding of the risk/benefit ratio of ransfusion in this high-risk patient population.. However, conincing data are unavailable to assess the relative risk associted with anemia/hemodilution compared with that of allogeeic transfusion. Article Title: Thrombin and Thrombin-Incorporated Biomaterials for Disease Treatments. Article Snippet: Thrombin, a coagulation-inducing protease, has long been used in the hemostatic field.. During the past decades, many other therapeutic uses of thrombin have been developed.. For instance, burn treatment, pseudoaneurysm therapy, wound management, and tumor vascular infarction (or tumor vasculature blockade therapy) can all utilize the unique and powerful function of thrombin. Article Title: Biomaterials as Haemostatic Agents in Cardiovascular Surgery: Review of Current Situation and Future Trends Article Snippet: .. From January 2008, Article Title: Recombinant human thrombin: safety and immunogenicity in pediatric burn wound excision. Article Snippet: Arizona Burn Center at Maricopa Medical Center, Phoenix, AZ, USA Joseph M Still Research Foundation, Augusta, GA, USA Shriners Hospital for Children Northern California, Sacramento, CA, USA Loyola University Medical Center, Maywood, IL, USA St. Christopher's Hospital for Children, Philadelphia, PA, USA University of New Mexico Health Sciences Center, Albuquerque, NM, USA University of Rochester, Rochester, NY, USA Seattle, WA, USA ZymoGenetics, a Bristol-Meyers Squibb Company, Seattle, WA 98102, USA Article Title: Protease Enzymes: Highlights on Potential of Proteases as Therapeutics Agents Article Snippet: In the era of advancement of biotechnology and molecular biology, the structure, catalytic site specification, role in biochemical processes, and many diseases of an enzyme have been discovered.. Enzymes are protein in nature and are formulated in the human body from amino acids.. Each enzyme carries its specific functions in the body and has particular substrates to work with. Clinical Proteomics:Article Title: Bleeding and management of coagulopathy. Article Snippet: The first available thrombin was derived from bovine plasma (Thrombin-JMI, King Pharmaceuticals, Bristol, Tenn). .. Bovine thrombin currently should be avoided because of its potential for antibovine thrombin antibody formation and immune-mediated coagulopathy.37 Currently, there are 2 human thrombins available for clinical use, including plasma-derived thrombin (Evithrom; Omrix, Somerville, NJ, and Johnson & Johnson, New Brunswick, NJ) and Article Title: Managing clotting Article Snippet: Purpose of review Bleeding in a perioperative setting occurs due to multiple causes, but newer anticoagulant and antiplatelet therapies are increasingly used preoperatively.. As a result, patients often can present for surgery with underlying hemostatic disorders due to these acquired disorders or following major surgery or trauma.. Because bleeding occurs due to multiple causes, the addition of pharmacologic agents creates an acquired defect that complicates the surgical injury and may result in increased blood loss. Coagulation:Article Title: Update on blood conservation for cardiac surgery. Article Snippet: t n a t PATIENTS UNDERGOING CARDIAC SURGERY are at risk of excessive bleeding, leading to increased usage of allogeneic blood and hemostatic blood products.. Although this patient population represents a relatively small proportion of surgical patients, cardiac surgery consumes about 20% of the available blood supply in the United States,1 with similar numers reported worldwide.2,3 The potential for beneficial effects of transfusing blood to maintain tissue oxygen perfusion and prevent organ ischemia may be greatest in patients with cardiovascular disease.4 Indeed, life-threatening hemorrhage, an absolute indication for blood transfusion, may be relatively frequent in these patients, with repeat surgery for bleeding occurring in up to 5% of patients.5,6 In addition, the risks of reexisting anemia and acute perioperative hemodilution have ecome more apparent.7,8 However, there is a lack of clinical utcome data to support the liberal use of blood transfusion in ardiac surgery.9 In contrast, there is a growing body of evidence demonstrating that blood product transfusion is associated with an increased risk of morbidity and mortality.10-12 The considerable ariability in the transfusion of blood and blood products (8% o 98%) among institutions13-15 and countries13,14,16 may reflect he lack of a clear understanding of the risk/benefit ratio of ransfusion in this high-risk patient population.. However, conincing data are unavailable to assess the relative risk associted with anemia/hemodilution compared with that of allogeeic transfusion. Food & Beverages:Article Title: Biomaterials as Haemostatic Agents in Cardiovascular Surgery: Review of Current Situation and Future Trends Article Snippet: .. From January 2008, |